Filtered By:
Source: Clinical Lung Cancer
Therapy: Radiation Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 224 results found since Jan 2013.

Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer
CONCLUSION: SBRT is a safe and viable treatment option for oligoprogressive and oligorecurrent NSCLC. Patients with 0 to 2 sites had better OS and longer TNT-D compared to those with 3 to 5 lesions.PMID:37714807 | DOI:10.1016/j.cllc.2023.08.015
Source: Clinical Lung Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Maryam Ebadi Colton Ladbury Jason Liu Adam Rock Mykola Onyshchenko Victoria Villaflor Miguel Villalona-Calero Ravi Salgia Erminia Massarelli Percy Lee Terence Williams Arya Amini Source Type: research

The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib
CONCLUSIONS: This is the first report to our knowledge of a patient who presented with gastric and hepatic metastases from lung cancer and achieved complete remission with osimertinib and local radiotherapy, with good quality of life, which also provides a basis for future clinical work and is of great significance.PMID:37695388 | DOI:10.1007/s00432-023-05386-7
Source: Clinical Lung Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Yun Wang Chao Yan Chuantao Zhang Enhao Yu Kai Wang Xiangyong Liu Jie Yu Chunyang Zhou Aijie Yang Source Type: research

Pathologic Nodal Staging Before SBRT for Early-stage NSCLC Does Not Impact Overall Survival: A Propensity Score-matched NCDB Analysis
CONCLUSIONS: SBRT use in early-stage NSCLC steadily increased over the study period. Most patients proceeded to SBRT without nodal staging, conflicting with National Comprehensive Cancer Network (NCCN) guidelines which recommend pathologic mediastinal lymph node evaluation for all early-stage NSCLC cases, except stage IA. Our findings suggest similar OS in patients with early-stage NSCLC treated with SBRT irrespective of nodal staging. Furthermore, we highlight patient-related, disease-related, and treatment-related prognostic factors to consider when planning therapy for these patients.PMID:37679872 | DOI:10.1097/COC.0000000000001040
Source: Clinical Lung Cancer - September 8, 2023 Category: Cancer & Oncology Authors: James N Cantrell Pawan Acharya Sara K Vesely Tyler C Gunter Source Type: research

Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective
JTO Clin Res Rep. 2023 Jul 26;4(9):100553. doi: 10.1016/j.jtocrr.2023.100553. eCollection 2023 Sep.ABSTRACTLife-prolonging central nervous system active systemic therapies for metastatic NSCLC have increased the complexity of managing brain metastases (BMs). Australian medical oncologists, radiation oncologists, and neurosurgeons discussed the evidence guiding the diverse clinical approaches to the management of BM in NSCLC. The Australian context is broadly applicable to other jurisdictions; therefore, we have documented these discussions as principles with broader applications. Patient management was stratified according...
Source: Clinical Lung Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Chee Khoon Lee Yu Yang Soon Rosalind L Jeffree Rohit Joshi Eng-Siew Koh Wei-Sen Lam Hien Le Zarnie Lwin Mark B Pinkham Shankar Siva Evan Ng Thomas John Source Type: research

Radiation-sensitive genetic prognostic model identifies individuals at risk for radiation resistance in head and neck squamous cell carcinoma
CONCLUSIONS: Our prognostic model based on a radiation-related gene signature has potential for application as a tool for risk stratification of radiation therapy for patients with HNSCC, helping to identify candidates for radiation therapy and overcome radiation resistance.PMID:37656244 | DOI:10.1007/s00432-023-05304-x
Source: Clinical Lung Cancer - September 1, 2023 Category: Cancer & Oncology Authors: Peimeng You Shengbo Liu Qiaxuan Li Daipeng Xie Lintong Yao Chenguang Guo Zefeng Guo Ting Wang Hongrui Qiu Yangzhong Guo Junyu Li Haiyu Zhou Source Type: research

Developing a Prediction Model for Radiation Pneumonitis in Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy Combined With Clinical, Dosimetric Factors, and Laboratory Biomarkers
CONCLUSION: Age, lung volume, fractional dose, V10, and Hb levels were demonstrated to be significant factors associated with grade ≥2 RP for lung cancer patients after SBRT. A novel model combining clinical, dosimetric factors, and laboratory biomarkers improved predictive performance compared with the clinical and dosimetric model alone.PMID:37648569 | DOI:10.1016/j.cllc.2023.08.007
Source: Clinical Lung Cancer - August 30, 2023 Category: Cancer & Oncology Authors: Bao-Tian Huang Pei-Xian Lin Ying Wang Li-Mei Luo Source Type: research

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
CONCLUSIONS: The findings indicate that the novel SBRT + LDRT + sintilimab therapy is safe and promising in patients with PD-L1-positive, driver gene-negative primary metastatic NSCLC.PMID:37581611 | DOI:10.1158/1078-0432.CCR-23-0315
Source: Clinical Lung Cancer - August 15, 2023 Category: Cancer & Oncology Authors: Xiaojuan Zhou Laiyan Zhou Zhuoran Yao Meijuan Huang Youling Gong Bingwen Zou Jiang Zhu Yongmei Liu Feng Peng Yan Zhang Min Yu Yanying Li Feifei Na Yijun Wu Kai Kang Weigang Xiu Xuanwei Zhang Lin Zhou Yong Xu Jin Wang Yan Wang Xue Yang Yuanjun Wu Rui Li Yu Source Type: research

The incorporation of cognitive-sparing techniques into prophylactic cranial irradiation in the management of small cell lung cancer
This article reviews the role of PCI and cognitive-sparing techniques in the management of SCLC.PMID:37574573 | DOI:10.21037/cco-23-12
Source: Clinical Lung Cancer - August 13, 2023 Category: Cancer & Oncology Authors: Julie R Bloom Alexandra Hotca Daniel R Cherry Daniel R Dickstein Juliana Runnels Robert M Samstein Rajwanth R Veluswamy Kenneth E Rosenzweig Paul D Brown Daniel M Trifiletti Joshua D Palmer Raj Singh William G Breen Eric J Lehrer Source Type: research

18F-FES Uptake in Radiation Pneumonitis
Clin Nucl Med. 2023 Aug 3. doi: 10.1097/RLU.0000000000004788. Online ahead of print.ABSTRACT18F-FDG uptake in radiation pneumonitis is well documented; however, the same is less so for 18F-floroestradiol (FES), which specifically binds to the estrogen receptors in vivo. We observed increased FES uptake in the right lung of an estrogen receptor positive breast cancer patient who had undergone right modified radical mastectomy followed by radiation therapy to chest wall. The possibility of FES uptake in radiation pneumonitis must therefore be kept in mind while interpreting FES PET.PMID:37566798 | DOI:10.1097/RLU.0000000000004788
Source: Clinical Lung Cancer - August 11, 2023 Category: Cancer & Oncology Authors: Aparna Mahalik Beena Chaudhary Rakesh Kumar Madhavi Tripathi Chandrasekhar Bal Source Type: research